Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchLufotrelvirLufotrelvir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

    
  
Lufotrelvir for COVID-19
1 study from 1 group
COVID-19 Lufotrelvir studies. Jul 2024. c19early.org
0 0.5 1 1.5+ All studies -22% Mortality -22% RCTs -22% Late -22% Favorslufotrelvir Favorscontrol
Feb 9
Grandits et al., NCT05780541 PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/​TICO Treatment Trial)
22% higher mortality (p=0.77) and 44% higher hospital discharge (p=0.11). RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
Jul 10
2023
Robinson et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad355 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
Phase 1 safety and pharmacokinetic study of lufotrelvir in 25 hospitalized COVID-19 patients. No adverse events or serious adverse events were considered related to lufotrelvir. Concentrations of lufotrelvir and its active moiety increase..
Nov 11
2022
Chen et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.1035969 Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection
Review of preclinical data for lufotrelvir and active metabolites for SARS-CoV-2. Lufotrelvir (PF-07304814) is a phosphate ester prodrug that is rapidly metabolized by alkaline phosphatase into the active compound PF-0835231, which suppre..
Oct 26
2022
Zhu et al., Clinical Pharmacology in Drug Development, doi:10.1002/cpdd.1174 Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants
Phase 1 randomized, double-blind, placebo-controlled study of 15 healthy participants showing safety and tolerability of single ascending 24-hour IV infusions of lufotrelvir (PF-07304814), a phosphate prodrug protease inhibitor targeting ..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit